GABAergic neurons in the nucleus accumbens core mediate the antidepressant effects of sevoflurane

Eur J Pharmacol. 2023 May 5:946:175627. doi: 10.1016/j.ejphar.2023.175627. Epub 2023 Mar 1.

Abstract

General anaesthetics have been widely applied to induce reversible loss and recovery of consciousness in clinical practice and have been shown to have reliably safe profiles. Since brief exposure to general anaesthetics can result in long-lasting and global changes in neuronal structures and function, these drugs also exhibit strong therapeutic potential for mood disorders. Preliminary and clinical studies have suggested that the inhalational anaesthetic drug sevoflurane might relieve symptoms of depression. However, the antidepressant effects of sevoflurane and the underlying mechanisms remain elusive. In the present study, we confirmed that the antidepressant and anxiolytic effects of inhaling 2.5% sevoflurane for 30 min were comparable to those of ketamine and could be sustained for 48 h. Activation of GABAergic (γ-aminobutyric acidergic) neurons in the nucleus accumbens core by chemogenetics was shown to mimic the antidepressant effects of inhaled sevoflurane, whereas inhibition of these neurons significantly prevented these effects. Considered together, these results suggested that sevoflurane might exert rapid and long-lasting antidepressant effects via modulation of neuronal activities in the nucleus accumbens core nucleus.

Keywords: Antidepressant; Chemogenetics; GABAergic neurons; Nucleus accumbens; Sevoflurane.

MeSH terms

  • Anesthetics, Inhalation* / pharmacology
  • Antidepressive Agents / pharmacology
  • GABAergic Neurons
  • Nucleus Accumbens*
  • Sevoflurane / pharmacology

Substances

  • Sevoflurane
  • Antidepressive Agents
  • Anesthetics, Inhalation